HIV triple therapy tablet containing new version of tenofovir

Odefsey (rilpivirine/emtricitabine/tenofovir alafenamide) is indicated in the treatment of patients aged 12 years and over and weighing at least 35kg who are infected with HIV-1 without known mutations associated with resistance to NNRTIs, tenofovir or emtricitabine and who have a viral load ≤100,000 HIV-1 RNA copies/ml. The 25mg/200mg/25mg tablet should be taken once daily with food.

Further information
View Odefsey drug record
Summary of Product Characteristics
Manufacturer: Gilead Sciences

Gilead also markets Eviplera, a similar product containing rilpivirine 25mg and emtricitabine 200mg but with a different tenofovir salt (tenofovir disoproxil 245mg).

Tenofovir alafenamide is a novel targeted prodrug of tenofovir which has high antiviral efficacy similar to tenofovir disoproxil but at a significantly lower dose (25mg versus 245mg).

As a result, Odefsey may be used in patients with moderate renal impairment (CrCl ≥30ml/min) while Eviplera is contraindicated if creatinine clearance is below 50ml/min. In addition, Eviplera is associated with a risk of reduced bone mineral density, especially when used in combination with a boosted protease inhibitor and alternative regimens should be considered in patients with osteoporosis and a high fracture risk. No such warning applies to the use of Odefsey.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases